Northern Trust’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Northern Trust’s Portfolio ARDS Stock Details ARDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-28,104	Closed	-$6.18K	–	4601
2023 Q2	$6.18K	Hold	28,104	–	–	﹤0.01%	4502
2023 Q1	$8.83K	Hold	28,104	–	–	﹤0.01%	4534
2022 Q4	$33.2K	Hold	28,104	–	–	﹤0.01%	4384
2022 Q3	$26K	Buy	28,104 +11,532	+70%	+$17.9K	﹤0.01%	4505
2022 Q2	$18K	Hold	16,572	–	–	﹤0.01%	4643
2022 Q1	$29K	Hold	16,572	–	–	﹤0.01%	4630
2021 Q4	$39K	Hold	16,572	–	–	﹤0.01%	4632
2021 Q3	$61K	Buy	+16,572	New	+$76.6K	﹤0.01%	4502

Other funds holding ARDS

Wealth Architects Mountain View, California $1.27B AUM 36.93% 1-Year Est. Return

Northern Trust's ARDS Position: Q3 2023 in Review

Northern Trust sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q3 2023, closing a stake of 28,104 shares — an estimated $6.18K sold.

Northern Trust first reported a position in ARDS in Q3 2021 and held it in 8 quarters. The position peaked at $61K in Q3 2021. 1 fund tracked by Wall St. Rank holds ARDS as of Q3 2023.

Northern Trust reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Northern Trust sold 28,104 Aridis Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $6.18K.
Northern Trust first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Northern Trust's Aridis Pharmaceuticals Inc. Common Stock position peaked at $61K in Q3 2021.
1 fund tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q3 2023.

Based on Northern Trust's 13F filing for Q3 2023, filed 13 Nov 2023.